b2b53efa-8a7b-4871-b6bb-6ebfb5cc0cea
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 69.5824777549624
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- IL6_JAK_STAT3_SIGNALING+0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- TNFA_SIGNALING_VIA_NFKB+0.350
- MYOGENESIS+0.330
- ANGIOGENESIS+0.320
- UV_RESPONSE_UP+0.300
- COAGULATION+0.290
- INFLAMMATORY_RESPONSE+0.290
- APICAL_JUNCTION+0.270
Top 10 suppressed
- PROTEIN_SECRETION-0.440
- ANDROGEN_RESPONSE-0.360
- MITOTIC_SPINDLE-0.350
- G2M_CHECKPOINT-0.340
- E2F_TARGETS-0.210
- SPERMATOGENESIS-0.180
- UV_RESPONSE_DN-0.170
- PEROXISOME-0.150
- BILE_ACID_METABOLISM-0.120
- PANCREAS_BETA_CELLS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | b9189c77-004e-461a-9c15-b504b12a3030 | — | — | 0.892 |
| 2 | SAMN03290885 | — | — | 0.870 |
| 3 | BS_HZRM07TW | Med | Medulloblastoma | 0.862 |
| 4 | 6bc70f5c-fdba-4bef-865a-793b7782a107 | — | — | 0.849 |
| 5 | 131e315e-6653-4199-b653-42b81644dad9 | — | — | 0.832 |
| 6 | BS_J8VX4D17 | Posterior Fossa Ependymoma | — | 0.823 |
| 7 | 02faba9d-8eda-4967-995d-61a0c13b843c | — | — | 0.822 |
| 8 | TCGA-DK-AA74-01A-11R-A39I-07 | — | — | 0.821 |
| 9 | 966a66a2-8aac-41e8-8007-88fd92d2e8e8 | — | — | 0.820 |
| 10 | SRR3147742 | — | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.180 | Inavolisib | — uncovered |